Ensign Group Inc header image

Ensign Group Inc

ENSG

Equity

ISIN null / Valor 3109721

NASDAQ (2026-11-06)
USD 181.08-0.72%

Ensign Group Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

The Ensign Group, Inc. operates through its independent subsidiaries, offering a comprehensive range of services across the healthcare spectrum, particularly focusing on post-acute care. This includes skilled nursing and assisted living facilities, alongside a variety of rehabilitative services such as physical, occupational, and speech therapies. Expanding beyond its traditional scope, The Ensign Group has ventured into additional post-acute care services, which encompass mobile x-ray, laboratory services, non-emergency transportation, and consulting services. These offerings are designed to meet a broad array of patient needs across several states, indicating The Ensign Group's commitment to providing a holistic approach to healthcare and rehabilitation.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (22.10.2026):

The Ensign Group, Inc. reported results for the second quarter of 2026, with GAAP diluted EPS of $1.68 and adjusted EPS of $1.92 on consolidated revenue of $1.44 billion. GAAP net income was $99.7 million (adjusted net income $114.3 million). Management raised 2026 guidance to $7.75–$7.85 of diluted EPS and revenue guidance to $5.87–$5.92 billion, citing stronger occupancy, skilled mix improvements and continued disciplined acquisitions.

Earnings & revenue

Q2 2026 GAAP diluted EPS $1.68 (up 16.7% YoY); adjusted diluted EPS $1.92 (up 20.8% YoY). GAAP net income $99.7M (up 18.2% YoY); adjusted net income $114.3M (up 22.5%). Consolidated revenue for the quarter was $1.440B, +17.3% vs. Q2 2025.

Guidance raised

Full-year 2026 guidance increased to $7.75–$7.85 diluted EPS (midpoint ≈ +18.7% vs. 2025) and revenue guidance to $5.87–$5.92B, up from prior ranges due to Q2 strength.

Clinical performance

Same Facilities outperformed peers: CMS Quality Measure ratings 23% better and CMS Cycle 1 survey results 18% better than state peers. Over 80% of skilled nursing operations have 4–5 star CMS ratings; rehospitalization and long-stay ED visit rates were 15% and 24% better than national averages, respectively. No Ensign-affiliated facility (of 398) is a CMS Special Focus Facility.

Occupancy & skilled mix

Same Facility occupancy 84.1% (up 2.7 pts YoY) and Transitioning Facility occupancy 84.7% (up 2.3 pts YoY). Same Facility skilled mix revenue +10.1% and skilled days +6.2% YoY; Transitioning Facility skilled mix revenue +14.0% and skilled days +9.4% YoY. Medicare and managed-care revenue and days also improved year-over-year.

Acquisitions and portfolio growth

Ensign added 20 new operations in the quarter (all included real estate). Since 2024 the company has closed and transitioned 102 operations; total portfolio now 398 healthcare operations across 17 states. Ensign owns 183 real estate assets (144 operated by affiliates).

Standard Bearer (real estate) results

Standard Bearer rental revenue was $44.1M in Q2 (+40.2% YoY) and FFO for the segment was $24.7M (+34.6% YoY). Standard Bearer comprises 177 owned properties with long-term triple-net leases.

Balance sheet & liquidity

Cash on hand approximately $262.3M and $591.6M available capacity under the line of credit. Net cash provided by operating activities was $272.1M for the six months ended June 30, 2026; investing activity reflected acquisitions and increased capex.

Non-GAAP metrics and disclosures

Management provided reconciliations to GAAP: adjusted EPS and adjusted net income exclude items such as stock-based compensation, acquisition costs and system implementation costs. Adjusted EBITDA for Q2 was $181.1M and adjusted EBITDAR $247.6M.

Shareholder returns

The company paid a quarterly cash dividend of $0.065 per share and reiterated its intent to continue dividends, noting strong liquidity supports ongoing payouts.

Summarized from source with an LLMView Source

Key figures

-1.00%1Y
77.9%3Y
118%5Y

Performance

27.5%1Y
25.4%3Y
26.8%5Y

Volatility

Market cap

10564 M

Market cap (USD)

Daily traded volume (Shares)

292,122

Daily traded volume (Shares)

1 day high/low

134.02 / 132.235

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Biogen Inc
Biogen Inc Biogen Inc Valor: 1720684
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.81%USD 248.35
Zydus Lifesciences Limited
Zydus Lifesciences Limited Zydus Lifesciences Limited Valor: 29835501
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.12%INR 1,195.00
IPCA Laboratories Limited
IPCA Laboratories Limited IPCA Laboratories Limited Valor: 115718957
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.35%INR 1,942.95
AnaptysBio, Inc.
AnaptysBio, Inc. AnaptysBio, Inc. Valor: 29675116
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.91%USD 46.45
LeMaitre Vascular inc
LeMaitre Vascular inc LeMaitre Vascular inc Valor: 2755054
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.11%USD 80.89
GSK PLC
GSK PLC GSK PLC Valor: 120042705
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.16%USD 50.33
Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited Valor: 3195888
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.32%INR 2,592.85
GSK PLC
GSK PLC GSK PLC Valor: 119642297
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%GBP 18.90
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC Hikma Pharmaceuticals PLC Valor: 2324471
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.77%GBP 16.50
Piramal Pharma Limited
Piramal Pharma Limited Piramal Pharma Limited Valor: 114197705
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.17%INR 239.20